Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Ibrutinib-related atrial fibrillation common, predicted by left atrial volume index

13 Jun 2019

Ibrutinib-related atrial fibrillation (IRAF) occurs more frequently than previously reported, with the left atrial volume index (LAVI) independently predicting such events, a study has found.

Researchers performed standardized monitoring in 53 consecutive patients (median age, 70 years; 74 percent male; median body mass index, 25 kg/m2) prior to and during ibrutinib therapy.

IRAF occurred in 14 patients (26 percent) after a median of 13 months, resulting in an incidence rate of 25.0 per 100 person-years. The cumulative incidence rate of IRAF was 21 percent at 6 months, 23 percent at 12 months and 38 percent at 24 months. The majority of events occurred in asymptomatic patients within a median time of 5.5 months.

Of note, the incidence of IRAF at 2 years was 15 times higher than the risk of atrial fibrillation observed in both the general population and chronic lymphocytic leukaemia patients not exposed to ibrutinib (p<0.0001).  

The risk of developing IRAF was significantly higher in the presence of LAVI ≥40 mL/m2 at treatment initiation. None of the patients on ibrutinib had major bleeding events, although the majority of patients with IRAF received anticoagulants.

The present data highlight the importance of performing standardized and close monitoring of asymptomatic patients in the first few months following initiation of ibrutinib, the researchers said. Furthermore, LAVI measurement may help identify patients at high risk and that anticoagulants could be considered in the absence of significant bleeding risk.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.